Phaseline

Companies › Inventage Lab.

Inventage Lab.: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IVL3003
Donepezil long-acting injection
ACHEPhase 1Alzheimer Disease–
IVL3004
Opioid receptor antagonist (long-acting injection)
OPRM1Phase 1Opioid Dependence–
IVL4002
Opioid receptor antagonist (long-acting injection)
OPRM1Phase 1Opioid Dependence–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05345509IVL3003Phase 1Alzheimer DiseaseNeurologyNov 2025
NCT05620940IVL3004Phase 1Opioid DependenceNeurologyDec 2025
NCT05620940IVL4002Phase 1Opioid DependenceNeurologyDec 2025

Targets

OPRM1 (2) ACHE (1)

Companies with the same targets

Supernus Pharmaceuticals Trevi Therapeutics Shionogi Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Ensysce Biosciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.